ARV Treatment of PLWH, References

References Part II - ARV Treatment of PLWH

Specific References

1. Insight Start study group: Lundgren JD, Babiker AG, Gordin F et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27; 373(9):795-807

2. Cohen MS, Chen YQ, McAuley M et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission N Engl J Med 2016; 375:830-839.
DOI: 10.1056/NEJMoa1600693

3. Rodger, A. J., Cambiano, V., Bruun, T,et al for the PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent
gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective,
observational study. Lancet 2019, 393(10189), 2428–2438. http://doi.org/10.1016/S0140-6736(19)30418-0

4. Langewitz W, Denz M, Keller A, et al. Spontaneous talking time at start of consultation in outpatient clinic: cohort study. BMJ 2002;325:
682-683

5. Glass TR, De Geest S, Hirschel B, et al.; Swiss HIV Cohort Study. Self-reported non-adherence to antiretroviral therapy repeatedly
assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008;13(1):77-85

6. WHO 2003 p.95-107

7. Arroll, B., Goodyear-Smith, F., Crengle, S., Gunn, J., Fishman, T., Fallon, K., Hatcher, S. (2010). Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in Primary Care Population. Annals of Family Medicine, 8(4), 348-353

8. Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV AIDS treatment nonadherence: a review and meta-analysis. Acquir. Immune Defic Syndr. 2011 Oct 1; 58(2):181-7

9. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010 Jun 1;24(9):1243-50

10. a) Bowring AL, Gouillou M, Hellard M et al. Comparing short versions of the AUDIT in a community-based survey of young people. BMC Public Health. 2013 Apr 4;13(1):301 b) Manual for the Fast Alcohol Screen Test (FAST), available at http://www.dldocs.stir.ac.uk/documents/fastmanual.pdf c) Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202

11. Fehr J, Nicca D, Langewitz W, Haerry D, Battegay M. Assessing a patient’s readiness to start and maintain ART (Revision 2015). Available
at http://www.ready4therapy.ch/pdf/cART_english.pdf

12. NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med.
2019 Jul 24. doi: 10.1056/NEJMoa1904340

13. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 Jul 24. doi: 10.1056/NEJMoa190282

14. Ryom L, Lundgren J, EL-Sadr W et al for D:A:D Lancet HIV 2018 Jun:5(6): e291-e300

15. Halvas EK, Joseph K , Brandt L et al. Nonsuppressible viremia on ART from large cell clones carrying intact proviruses. CROI 2019. Oral abstract 23

16. Zash R, Holmes L, Diseko M, et al. Neural Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019 Jul 22 doi: 10.1056/NEJMoa1905230

17. Török ME et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis2011 Jun 1; 52:1374

18. Meintjes, G., Stek, C., Blumenthal, L., et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. New England
Journal of Medicine 2018, 379(20), 1915–1925. http://doi.org/10.1056/NEJMoa180076

19. De Castro N, Marcy O, Chazallon C, et al for ANRS 12300 Reflate TB2 study group. Virologic efficacy of Raltegravir vs. Efavirenz based
antiretroviral treatment in HIV1-infected adults with tuberculosis: w48 results of the ANRS 12300 REFLATE TB2 Trial. IAS 2019.

20. Hare C, Coll J, Ruane P et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. CROI 2019. Abstract # 104

General References

Mondi A, Lorenzini P, Tavellli A et al., “Effectiveness of Single- vs Multiple-Tablet Regimens as First-Line ART in ICONA Cohort,” CROI 2019, #511

Gallant, J., Lazzarin, A., Mills, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017, 390(10107), 2063–2072. http://doi.org/10.1016/S0140-6736(17)32299-7

Walmsley SL, Antela A, Clumeck N, et al. SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.

Sax, P. E., Pozniak, A., Montes, M. L., et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GSUS- 380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017, 390(10107), 2073–2082. http://doi.org/10.1016/S0140-6736(17)32340-1

Cahn P, Sierra Madero J, Arribas JR et al. Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies. IAS 2019.

Molina, J.-M., Squires, K., Sax, P. et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. The Lancet HIV 2018, 5(5), e211–e220. http://doi.org/10.1016/S2352-3018(18)30021-3

Orkin, C., Squires, K. E., Molina, J.-M., et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clinical Infectious Diseases 2019, 68(4), 535–544. http://doi.org/10.1093/cid/ciy540

Raffi F, Babiker AG, Richert L et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3

Lennox JL, Landovitz RJ, Ribaudo HJ, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71

Llibre, J. M., Hung, C.-C., Brinson, C., Castelli, F., Girard, P. M., Kahl, L. P., et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018, 391(10123), 839–849. http://doi.org/10.1016/S0140-6736(17)33095-7

van Wyk J, Ajana F, Bisshop F et al. Switching to DTG + 3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 24 Weeks (TANGO Study). IAS 2019

Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for post-exposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S170-6

Molina J.-M., Charreau I, Spire B., et al. For ANRS IPERGAY study group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The Lancet HIV 2017, 4(9), e402–e410. http://doi.org/10.1016/S2352-3018(17)30089-9

McCormack S, Dunn DT, Desai M et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387: 53–60